Doctor of Podiatric Medicine Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Dimitrios Moustakas

Podiatrist Smyrna, DE Doctor of Podiatric Medicine

NPI 1982131173 CMS profile 7549565

315 N Carter Rd, Smyrna, DE 19977

Open in the dashboard

General payments

$6,688

75 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dimitrios Moustakas of Smyrna, DE is reported in the CMS Open Payments database as having received $6,688 across 75 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $871 10
2024 General $770 17
2023 General $1,008 27
2022 General $1,625 18
2021 General $2,413 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dimitrios Moustakas
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Dimitrios Moustakas were reported at $871. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Dimitrios Moustakas Podiatrist median Middle half National median
2019 $0 $196 $72–$601 $163
2020 $0 $118 $38–$335 $114
2021 $2,413 $169 $57–$573 $132
2022 $1,625 $220 $74–$782 $149
2023 $1,008 $208 $71–$635 $160
2024 $770 $237 $87–$681 $164
2025 $871 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Supreme Orthopedic Systems, LLC $3,620 4 payments
  2. Smith+Nephew, Inc. $2,185 50 payments
  3. Organogenesis Inc. $228 4 payments
  4. Next Science LLC $174 2 payments
  5. Linvatec Corporation $103 1 payment
  6. Boston Scientific Corporation $99 1 payment
  7. Biocomposites Inc $47 1 payment
  8. Reapplix Inc. $44 2 payments
  9. Medtronic, Inc. $23 1 payment
  10. Novo Nordisk Inc $21 1 payment
  11. Other $143 8 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Education $3,600 3 payments
  2. Food and Beverage $3,088 72 payments
Products named General payments · program years 2021–2025
  1. GRAFIX PL Other Advanced Wound Management $812 20 payments
  2. STRAVIX Extremities & Limb Restoration $300 4 payments
  3. COLLAGENASE SANTYL $295 13 payments
  4. GRAFIX PL Other Advanced Wound Management $209 2 payments
  5. REGRANEX $186 8 payments
  6. GRAFIX Other Advanced Wound Management $163 6 payments
  7. GRAFIX Other Advanced Wound Management $161 2 payments
  8. STRAVIX Extremities & Limb Restoration $150 1 payment
  9. Xperience $144 1 payment
  10. BLASTX $144 1 payment
  11. Other $2,241 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

72

Median for Podiatry: 160

Drug cost

$1,474

Median for Podiatry: $2,368

Branded share of claims

15.3%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 25 $1,149
Mupirocin Generic 18 $122
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 11 $118
Meloxicam Generic 18 $85

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$69,088

Medicare's payments for the services billed

Medicare patients

392

Average age 75

Services billed

1,248

213 women, 179 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 64%
Diabetes 55%
Chronic kidney disease 41%
Ischemic heart disease 36%
Heart failure 24%
Atrial fibrillation 24%
COPD 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

75 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Delaware

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record